Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ (947,597)	$ (52,012)	$ 60,955
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Loss from Equity Method Investment in the Joint Venture	380,713	70,487	58,680
Depreciation and amortization	30,838
Accretion and changes in estimate, net	15,823
Tax receivable agreement charges	164,633
Equity compensation	1,701
Deferred income tax expense (benefit)	(143,822)	(18,595)	(119,621)
(Gain) Loss on Sale of Interests in the Joint Venture		(661)	(14)
(Gain) loss on other investments	(15,881)
Goodwill impairment charge	561,164
Amortization of debt discount and issuance costs	2,235
Other	(1,110)
Changes in operating assets and liabilities:
Accounts receivable	(21,211)
Prepaid expenses and other	(7,528)
Due from the Joint Venture	(2,516)	(72)	524
Income taxes receivable	1,309	14,047	(15,828)
Accounts payable	7,532
Accrued expenses and other liabilities	(195,207)	(125)	(524)
Deferred Revenue	11,304
Due to the Joint Venture	3,692	(9,661)	15,828
Net cash provided by (used in) operating activities	(153,928)	3,408
Cash flows from investing activities:
Proceeds from sale of interests in Joint Venture		6,503	171
Capitalized expenditures	(13,002)
Acquisitions, net of cash acquired	330,667
Investment in debt and equity securities of the Joint Venture	(278,875)
Proceeds from investments in debt securities of the Joint Venture	7,332
Investment in the Joint Venture	(610,784)
Net cash provided by (used in) investing activities	(564,662)	6,503	171
Cash flows from financing activities:
Proceeds from initial public offering, net of issuance costs	608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs	232,929
Proceeds from issuance of debt component of tangible equity units	47,367
Payment of loan costs	(1,421)
Repayment of senior amortizing notes	(11,094)
Proceeds from draw on revolver	250,000
Payments to acquire common stock		(6,502)	(171)
Receipts (payments) on derivative instruments	(890)
Net cash provided by (used in) financing activities	1,125,570	(6,502)	(171)
Effect of exchange rate changes on cash and cash equivalents	16
Net increase (decrease) in cash, cash equivalents and restricted cash	406,996	3,409
Cash, cash equivalents and restricted cash at beginning of period	3,409
Cash, cash equivalents and restricted cash at end of period	410,405	3,409
Supplemental disclosures of cash flow information
Cash paid for interest	265,633
Cash paid for income taxes	(714)		15,828
Issuance of common stock upon exercise of equity awards:
Investment in the Joint Venture	5,077	1,297	5,306
Dividend receivable	(5,077)	(1,297)	(5,306)
Change Healthcare Inc. portion of the Joint Venture equity transactions:
Investment in the Joint Venture	13,902	(2,377)	10,898
Additional paid in capital	(11,133)	(6,043)	(7,427)
Accumulated other comprehensive income	(2,769)	$ 8,420	$ (3,471)
Capitalized Expenditures:
Property and equipment, net	5,295
Other noncurrent assets, net	14,169
Intangibles, net	2,855
Drafts and accounts payable	(9,843)
Accrued expenses	$ (12,476)